Goldman Sachs likely to invest Rs 2,700 crore in PharmEasy parent

By Sumit Blogs -

Goldman Sachs is in advanced talks to invest about $350 million (Rs 2,700 crore) in API Holdings, the parent of online pharmacy PharmEasy, in a structured debt transaction, people in the know said.

The debt will carry an interest rate of 14-15% and also have a pre-agreed equity upside, or a premium to the rate based on potential increase in the company’s valuation, the people said. The money will predominantly be used to refinance the debt the company had taken to fund its acquisition of diagnostics chain

last year.

Goldman Sachs declined to comment while an email sent to API Holdings remained unanswered at press time Tuesday.

The company may raise another $200 million after closing the deal with the US financial services company, the people said.

PharmEasy, India’s largest online pharmacy, had plans to raise Rs 6,250 crore through an initial public offering of shares and use Rs 1,929 crore of that for paying off debt. A part of the debt payment is due by August 2022. The IPO plans were kept on hold due to weak market conditions.

PharmEasy was valued at $5.6 billion when a clutch of global funds invested $350 million in a pre-IPO round in October last year. Singapore-based Amansa Capital, hedge fund ApaH Capital, OrbiMed, Steadview Capital and Abu Dhabi’s sovereign wealth fund ADQ were among PharmEasy’s new investors.

PharmEasy turned a unicorn in April 2021, when Prosus Ventures, TPG and others led a $350 million Series-E round of funding at a valuation of $1.5 billion. After it acquired a 66% stake in Thyrocare in June 2021, the valuation shot up to $4 billion.

Prosus Ventures (previously Naspers Ventures) is the largest shareholder in the startup with a 12% stake. Singapore-based Temasek holds a 11% stake in the company, while TPG Growth owns 6.6% and Evermed Holdings has a 6% stake. As many as 43 investors hold about 70% of the company.

Credits – Source – https://ift.tt/dITmAgW

The post Goldman Sachs likely to invest Rs 2,700 crore in PharmEasy parent appeared first on Stay in Gurgaon.

Comments

Post a Comment

Popular posts from this blog

Flat sale of flu drugs hints at no unusual rise in infections

By Sumit Blogs -
Image
By Economic Times – Flat sale of flu drugs hints at no unusual rise in infections Industry executives and chemists said the April sales data showed a month-on-month decline of 30-40%. But even though the lockdown is seen to be impacting sales of most drugs, the pattern for medicines for infections and flus is no different.Last Updated: Apr 30, 2020, 11.23 AM ISTAgenciesExperts said the decline in sales was primarily because of the lockdown and other restrictions which forced people to stay indoors. (This story originally appeared in on Apr 30, 2020)NEW DELHI: Sales of anti-infectives (antibiotics and antivirals), respiratory drugs, painkillers and analgesics — some key medicines used for influenza-like illnesses — have remained mostly unchanged in last three months (January to March), partly explained by the lockdown but also indicating no unusual rise in flu-type infections that might point to a wider and undetected spread of Covid-19. Sales of most medicines, including this set of
Read more

10YearsForSimha: Reasons behind film’s success

By Sumit Blogs -
Image
By Times of India – 10YearsForSimha: Reasons behind film’s success TIMESOFINDIA.COM | Last updated on – Apr 30, 2020, 06:00 ISTclose01/6Take a look at the reasons behind the film’s successDirected by Boyapati Srinu, the 2010 film Simha was a game-changer among Tollywood films that was lauded, not only for Nandamuri Balakrishna’s intense performance in the dual role but also the gripping narration of the filmmaker. Balayya and Nayanthara were seen on the big screen for the first time ever in the film. The action drama made a special place in the hearts of the audience because of its simple storytelling, superhit songs and unbeatable chemistry between the lead pair. The movie has completed a decade, but the essence is as fresh as it was back then. As the film clocks 10 years of its release, find out the reasons behind the massive success of the Balakrishna starrer.readmore02/6​Boyapati Srinu’s gripping narrationBefore Simha, Boyapati Srinu had delivered Bhadra (2005) and Tulasi (2007),
Read more

Hrithik-Saif’s Vikram Vedha hits a roadblock

By Sumit Blogs -
Image
The stage was about to be set for Hrithik Roshan and Saif Ali Khan’s ‘Vikram Vedha’ in Mumbai’s Film City. The material had reached. The artisans had been hired. But the lights have now been dimmed. Madhavan and Vijay Sethupathi’s hit movie Vikram Vedha’s Hindi remake will not go on floors by mid-July as per the original plan. The new delta virus of COVID has sent shudders down many spines and many films which were being laid out on an expansive scale have been either held back or shifted their shoots abroad. The first schedule of this Hrithik-Saif movie will now be shot abroad. A source says, “The Mumbai schedule will be done but later.” Adds the source, “It’s a call that was taken yesterday. It wasn’t an easy call to take, no doubt, but the fact that it’s going to be a costly set made the makers take the safer route rather than be sorry later.” When contacted, General Secretary of FWICE (Federation of Western India Cine Employees), Ashok Dubey, confirmed that the makers of ‘V
Read more